Extended Data Fig. 6: Lack of human SLAMF6 or blockade with human SLAMF6 mAbs promotes T cell activation.
From: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer
a, Quantitative analysis of Fig. 4a. n = 3 donors per group. b, SLAMF6−/− variants of Jurkat cells were generated and subsequently analysed by flow cytometry. n = 4 for each cell population. c, Variants of Jurkat were activated with the indicated concentrations of CD3 mAb OKT3 or P + I. After 48 h, production of IL-2 was determined by ELISA. n = 3 for each cell population. d, Related to Fig. 4b. Quantification of TCR-regulated substrates at ∼100 kDa (p100) and ∼70 kDa (p70) was performed within each independent experiment, and values pooled from 3 independent experiments are shown. n = 3 for each cell population. e, Related to Fig. 4c, showing quantification of data from 3 independent experiments for calcium influx (Ca2+). n = 3 for each cell population. f, Same as Fig. 4d, except that other mAbs were analysed. n = 18 individual cell (Ctrl mAb), 15 individual cell (SLAMF6 mAb NT-7), 14 individual cell (SLAMF6 mAb 1B3, #5, #21), 13 individual cell (SLAMF6 mAb #23). g, Same as Fig. 4e, except that other mAbs were analysed. n = 3 donors per group. Error bars represent mean ± s.d. in a-g. Two-sided unpaired Student’s t-test were used (a-g). Numbers above data points represent p values. Results are pooled from 3 (a-g) independent experiments.
